Frontlight ResearchEarly access
Taking people in United StatesNo phase
TransCatheter Replacement Of the Mitral Valve With the Novel Cephea Mitral Valve System
Key facts
- Who runs it
- Abbott Medical Devices
- Where
- Wichita, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 565 people, planned
- Started
- 21 Oct 2026
- Expected to end
- 31 Dec 2035
- Type of study
- Interventional, 2 groups
- Treatments tested
- Cephea Mitral Valve System
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Mitral valve dysfunction meeting one of the following severity criteria:; Mitral Annular Calcification (MAC) associated with at least one of the following: i. Grade III or higher mitral regurgitation (MR) ii. Severe mitral stenosis (MS) iii. Concomitant moderate (Grade II) MR and moderate MS b. Grade III or higher MR of primary or secondary etiology
- The subject is deemed unsuitable for both conventional mitral valve surgery and transcatheter mitral valve repair
- NYHA functional class II or higher
- Left Ventricular Ejection Fraction of at least 25%
- Left Ventricular End Diastolic Dimension ≤ 75mm
- The Site Heart Team determines that the subject has been adequately treated per applicable standards for coronary artery disease, left ventricular dysfunction, cardiac arrhythmias, and heart failure
- 18 years of age or older
- The subject agrees to the study requirements and has provided written informed consent
Who cannot take part
- Currently participating in another investigational drug or device study that has not reached its primary endpoint
- Prior surgical or interventional treatment that can interfere with the Cephea Valve delivery or function
- Any planned surgery in the next 12 months that is expected to adversely impact mobility or the subject's quality of life
- Prior orthotopic heart transplantation
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's safety or ability to participate in the clinical investigation or to comply with the follow-up requirements, or impact the scientific soundness of the clinical investigation results
- Any planned cardiac surgery or intervention within the next 12 months
- Moderate or severe aortic stenosis, or aortic valve disease requiring surgery or transcatheter intervention
- Severe tricuspid or pulmonary valvular regurgitation, or valve disease requiring surgery or transcatheter intervention
- Evidence of right-sided congestive heart failure or severe right ventricular dysfunction
- Subject is undergoing dialysis or has chronic renal failure
- Subject has fixed pulmonary arterial hypertension
- Moderate to severe liver disease
- Known hypersensitivity or contraindication to procedural or post-procedural medications that cannot be adequately managed
- Known hypersensitivity to nickel or titanium that cannot be appropriately managed
- Chronic lung disease requiring continuous home oxygen therapy
- Iliofemoral venous anatomy that is insufficient for the introduction and delivery of the Cephea Valve or Delivery System
- Imaging evidence of intracardiac mass, vegetation, or thrombus at risk of embolization
- Unresolved severe carotid stenosis, or symptomatic carotid stenosis of any severity
- Hypertrophic or restrictive cardiomyopathy, or constrictive pericarditis that would interfere with Cephea Valve fit or function
- Transesophageal echocardiography (TEE) is contraindicated or high risk
- Modified Rankin Scale ≥ 4 disability
- Subject is pregnant or nursing and those who plan pregnancy during the clinical investigation follow-up period
This trial is currently available in United States.
- Ascension Via Christi Hospitals WichitaWichita, United StatesContact: Lindsey SteeleTaking people
About the trial
What the trial wants to find out
The objective of this clinical trial is to evaluate the safety and effectiveness of the Cephea Mitral Valve System in subjects with symptomatic mitral valve disease (MVD) or are deemed unsuitable for surgery and transcatheter repair.
The 2 groups in the trial
- Mitral Regurgitation CohortTreatment being tested
Inclusive of subjects who have moderate-to-severe or severe Mitral Regurgitation
Treatment: Cephea Mitral Valve System
- Mitral Annular Calcification (MAC) CohortTreatment being tested
Inclusive of subjects with mitral valve dysfunction associated with MAC
Treatment: Cephea Mitral Valve System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 13 November 2026